Cargando…
Therapeutic potential of ERK5 targeting in triple negative breast cancer
Triple negative breast cancers (TNBCs) account for 15% of all breast cancers, and represent one of the most aggressive forms of the disease, exhibiting short relapse-free survival. In contrast to other breast cancer subtypes, the absence of knowledge about the etiopathogenic alterations that cause T...
Autores principales: | Ortiz-Ruiz, María Jesús, Álvarez-Fernández, Stela, Parrott, Tracy, Zaknoen, Sara, Burrows, Francis J., Ocaña, Alberto, Pandiella, Atanasio, Esparís-Ogando, Azucena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294347/ https://www.ncbi.nlm.nih.gov/pubmed/25350956 |
Ejemplares similares
-
Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target
por: Montero, Juan Carlos, et al.
Publicado: (2009) -
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019) -
Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
por: Ocaña, Alberto, et al.
Publicado: (2016) -
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019) -
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
por: Sánchez-Fdez, Adrián, et al.
Publicado: (2021)